Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

(OP:MSCLF)

0.4114 +0.0206 (+5.27%)
Streaming Delayed Price Updated: 2:44 PM EDT, Jun 18, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 10,425
Open 0.4000
Bid (Size) N/A (0)
Ask (Size) N/A (0)
Prev. Close 0.3908
Today's Range 0.3925 - 0.4114
52wk Range 0.3310 - 0.9350
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Satellos Bioscience Shareholders Elect Two New Board Members
From Satellos Bioscience Inc.
Via Business Wire
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire

Performance

YTD
-34.8%
-34.8%
1 Month
-16.0%
-16.0%
3 Month
-22.6%
-22.6%
6 Month
-33.8%
-33.8%
1 Year
+5.9%
+5.9%

More News

Read More
Satellos Bioscience to Participate in PPMD’s Annual Conference in Las Vegas
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Satellos Reports First Quarter 2025 Results and Highlights Recent Company Progress
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at the CureDuchenne FUTURES National Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in Two April Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Satellos Reports 2024 Financial Results and Highlights Company Progress
From Satellos Bioscience Inc.
Via Business Wire
Satellos Presents Initial Data from the Phase 1 Trial of SAT-3247 at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Upcoming Presentation at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Completed Enrollment of all Four Multiple-Ascending Dose Cohorts for the Phase 1 Clinical Trial of SAT-3247 in Healthy Volunteers
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces First Participant with Duchenne Muscular Dystrophy Dosed in the Phase 1b Clinical Trial of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in Oppenheimer Movers in Rare Disease Summit
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in Duchenne KOL Investor Webinar on December 4, 2024
From Satellos Bioscience Inc.
Via Business Wire
Satellos Appoints Stephanie Brown to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Satellos Reports Q3 2024 Financial Results and Provides Clinical Update
From Satellos Bioscience Inc.
Via Business Wire
Satellos to Participate in November 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Participation in September 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
From Satellos Bioscience Inc.
Via Business Wire
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire

Frequently Asked Questions

Is MSCLF publicly traded?
Yes, MSCLF is publicly traded.
What exchange does MSCLF trade on?
MSCLF trades on the OTC Traded
What is the ticker symbol for MSCLF?
The ticker symbol for MSCLF is MSCLF on the OTC Traded
What is the current price of MSCLF?
The current price of MSCLF is 0.4114
When was MSCLF last traded?
The last trade of MSCLF was at 06/18/25 02:44 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.